Form 8-K Spyre Therapeutics, Inc. For: Nov 04
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $64.00 price target on the stock.MarketBeat
- Spyre Therapeutics (NASDAQ:SYRE) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SYRE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Can Spyre Therapeutics' (SYRE) Early SPY003 Results Mark a Turning Point in R&D Strategy? [Yahoo! Finance]Yahoo! Finance
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 12/3/25 - Form 4
- 11/5/25 - Form 4
- 11/4/25 - Form 10-Q
- SYRE's page on the SEC website